Jubilant Life Sciences has posted its second quarter results. Income from operations is reported at Rs 1,225crore, up 16 per cent, EBITDA at Rs 264crore, up 9 per cent and PAT at Rs 152 crore, up 92 per cent.
Commenting on the company’s performance, Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “We are happy to report that revenue and operating profit growth is in line with our expectations. Continued focus on enhancing market shares across business lines, new product launches in both segments and enhanced capacity utilisation would drive achievement of annual guidance given earlier.”
In Q2 FY13, income from Operations stood at Rs 1,225 crore showing 16 per cent YoY growth. The accompanying volume growth was 11 per cent. EBITDA at Rs 264 crore grew 9 per cent YoY with EBITDA margins of 21.5 per cent. Profit before exceptional items, tax and minority interest stood at Rs 144 crore. The reported profit after tax was at Rs 152 crore, up 92 per cent compared to last year same period on account of exceptional exchange gains. Normalised PAT stood at Rs 103 crore for Q2’FY13.
EP News Bureau